Aquestive Therapeutics resubmits NDA for Anaphylm
The company said it resubmitted its New Drug Application for Anaphylm after supportive human factors and pharmacokinetic study results.
Aquestive Therapeutics resubmitted its New Drug Application for Anaphylm following supportive human factors and pharmacokinetic study results.Key Highlights:Original SEC Filing: Aquestive Therapeutics, Inc. [ AQST ] - 8-K - Sep. 17, 2026This is an AI-powered summary. It may contain inaccuracies.
Co…